The field of apicomplexan transgenics has been transformed by selectable markers that couple metabolism, drug action, and genetic engineering. This review consolidates three decades of progress across model parasites, Toxoplasma, Plasmodium, Cryptosporidium, Neospora, Eimeria, Babesia, and Theileria, illustrating how selection markers have enabled genome engineering. We dissect the rationale and mechanisms underlying positive and negative drug selections and emphasize marker recycling. Practical guidance is paired with failure diagnostics that determine whether transgenic selections succeed in vitro or in vivo. Looking forward, we outline new directions for expanding the toolkit: exploiting auxotrophy, importing orthogonal resistance genes, and leveraging CRISPR-based marker-free editing. We discuss translational constraints, especially the need for self-excising or transient markers in vaccine research, adapting selection in nonmodel species and the value of selection marker cocktails for pathway-scale engineering. By integrating models, mechanisms, methods, and modalities, this article provides a rigorous framework for parasite engineering and a clear path to novel orthogonal, host-sparing selection strategies.
Peddiraju et al. (Tue,) studied this question.